GENERATIONAL EQUITY

Successful Urology Medical Practice #68787 Sign NDA ► Location: S. California 2025 Est. Revenue $4,100,000 2025 Est. EBITDA $780,000 DISCLAIMER: All information contained in this document has been provided by the subject company to Generational Equity and while believed to be correct has not been verified. Accordingly, Generational Equity makes no representations or warranties as to the accuracy and truthfulness of such information. The recipient hereof acknowledges that Generational Equity shall not be liable for any loss or injury suffered by said recipient in any way connected to the delivery by Generational Equity of this document. At all times Generational Equity and its affiliate network members is an agent for the seller and not for the buyer. Generational Equity's fees are paid by the seller. Mike Meredith Managing Director - M&A Email: mmeredith@generational.com Office: 949-423-5255 Generational Equity, LLC 3400 N. Central Expressway, Ste. 100 Richardson, TX 75080 Fax: 972-392-8564 BUSINESS HIGHLIGHTS This outstanding acquisition opportunity is for a four-physician medical practice specializing in urology. The Company's physicians are board-certified by the American Board of Urology and offer a comprehensive, full-service specialty practice, providing consultations and surgical procedures, for many procedures including robotic, laparoscopic, minimally- invasive procedures for treatment of urological cancers and benign conditions, complex female pelvic floor reconstruction for incontinence and more. INVESTMENT BANK OF THE YEAR 2018 - 2022 - 2024 INVESTMENT APPEAL • Superior Name & Reputation — The Company is a well-established medical practice offering state of the art urology treatment. It has an excellent online reputation (Yelp and Google reviews) and receives numerous word of mouth referrals from family members and friends. Revenue is the result of the Company's established reputation in its area. • Experienced Non-Owner Key Personnel — The Company's non-shareholder medical staff include two board-certified urologists. • Limited Competition, Growth Opportunities — The Company has very limited competition in its local market and has a steady stream of patient referrals and room to grow, given additional physician staffing. • Strong Projected Industry Performance — US personal consumption expenditures on physicians are forecast to grow at an annual compounded rate of 5% between 2024 and 2029. During the same period, the Company's proforma projections are expected to grow by a CAGR of 7.7%, beating the industry average for the same period.

• Cover